Hamburg Details Some Sequestration Impact On FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner says allowing the sequester would slow implementation of FDASIA provisions and reduce some overseas inspections.
You may also be interested in...
Sequestration Kicks In: FDA Will Manage For Now, But Could Suffer Aftereffects
With the implementation of across-the-board spending cuts, FDA will be unable to add the hundreds of new employees needed to meet the goals of user-fee and other programs, a paucity that could damage the agency for years to come.
Sequestration Day: FDA Will Manage For Now, But Could Suffer Later If Hiring Deferred
As the across-the-board cuts go into effect, not allowing FDA to add the hundreds of new employees that will be needed to meet the goals of user fee and other programs could damage the agency for years to come; NIH and CMS also will see significant effects.
FDA Talking To Industry About Releasing “Complete Response” Letters
Commissioner Hamburg says conversations are underway with industry to allow the agency to release its reasons for not approving a product, in part so others will not waste funds repeating known failures. FDA is also working to remove user fee revenue from sequestration.